Liang Xu
Tianjin University of Traditional Chinese Medicine(CN)Nanjing University of Chinese Medicine(CN)Wenzhou Medical University(CN)Soochow University(CN)Tianjin Infectious Diseases Hospital(CN)Jinan Central Hospital(CN)Tianjin People's Hospital(CN)Wuxi Ninth People's Hospital(CN)Second Hospital of Tianjin Medical University(CN)Second Affiliated Hospital of Nanjing Medical University(CN)Xian Yang Central Hospital(CN)Shandong First Medical University(CN)Tianjin Medical University(CN)
Publications by Year
Research Areas
Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, Glaucoma and retinal disorders, Hepatitis C virus research, Adipokines, Inflammation, and Metabolic Diseases
Most-Cited Works
- → SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice(2017)482 cited
- → DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization(2016)191 cited
- → Roles of Chemokines and Chemokine Receptors in Obesity-Associated Insulin Resistance and Nonalcoholic Fatty Liver Disease(2015)187 cited
- → Glucoraphanin Ameliorates Obesity and Insulin Resistance Through Adipose Tissue Browning and Reduction of Metabolic Endotoxemia in Mice(2017)175 cited
- → Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization(2017)130 cited
- → Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet